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Abstract
Objective:  A fatality in one multiple sclerosis (MS) patient due to acute idiopathic
thrombocytopenic purpura (ITP) and a near fatality in another stimulated our interest in platelet
function abnormalities in MS. Previously, we presented evidence of platelet activation in a small
cohort of treatment-naive MS patients.
Methods: In this report, 92 normal controls and 33 stable, untreated MS patients were studied.
Platelet counts, measures of platelet activation [plasma platelet microparticles (PMP), P-selectin
expression (CD62p), circulating platelet microaggragtes (PAg)], as well as platelet-associated IgG/
IgM, were carried out. In addition, plasma protein S activity was measured.
Results: Compared to controls, PMP were significantly elevated in MS (p < 0.001) and CD62p
expression was also markedly elevated (p < 0.001). Both are markers of platelet activation. Platelet-
associated IgM, but not IgG, was marginally elevated in MS (p = 0.01). Protein S in MS patients did
not differ significantly from normal values.
Conclusion: Platelets are significantly activated in MS patients. The mechanisms underlying this
activation and its significance to MS are unknown. Additional study of platelet activation and
function in MS patients is warranted.
Background
The fatal outcome in one of two multiple sclerosis (MS)
patients with idiopathic thrombocytopenic purpura (ITP)
prompted our interest in platelet activity and function in
the context of MS. Although Putnam investigated a possi-
ble role of venule thrombosis as a factor in central nervous
system (CNS) demyelination in 1935 [1], a role for plate-
lets in CNS demyelination was not further considered
until a series of papers in the 1960s, such as that of Wright
et al. [2] For example, Nathanson and Savitsky [3]
employed a measure of platelet adhesiveness in 132 sub-
jects, 60 of whom had MS. The investigators reported
increased platelet adhesiveness in both MS and Guillain-
Barre correlating with disease activity. Although other
investigations confirmed their findings, they contributed
little additional information. More recently, a central role
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for platelets in inflammation has emerged, as reviewed
[4,5].
Our observation of platelet abnormalities in MS [6] and
subsequent observation of thrombosis in cutaneous
venules and capillaries adjacent to subcutaneous ulcers
complicating subcutaneous injections of interferon-
beta1b [7] heightened our interest in a possible role of
platelet dysfunction in MS. To investigate the basis of
these observations, we have applied the flow cytometric
analysis of platelet-derived microparticles (PMP) and
CD62p expression, as well as other more conventional
assays. For this study, we employed consecutively
recruited patients and measured, in addition to routine
tests such as platelet counts, the expression of platelet acti-
vation marker P-selectin (CD62p), platelet microparticles
(PMP) in plasma, platelet micro-aggregates (PAg), protein
S activity, and platelet-associated immunoglobulins IgG
and IgM, as described following.
Methods
Patient population
Thirty-three treatment-naïve, clinically stable relapsing-
remitting MS patients and 92 normal control subjects
were recruited. The study protocol was approved by the
IRB office of University of Miami and signed informed
consents were obtained.
Blood sampling
A 4.5 mL blood sample was drawn into Vacutainer® tubes
containing citrate, using a 21-gauge butterfly needle fol-
lowing light application of a tourniquet. After blood flow
was established, the tourniquet was promptly removed to
minimize artifactual platelet activation. The first tube
drawn was not used for platelet studies to avoid platelet
activation from thromboplastin released by the puncture
wound. Samples were prepared for flow cytometry not
more than 2 hours after phlebotomy. Although drawing
into Vacutainers induces slight platelet activation com-
pared to the syringe method, they were required by the
phlebotomy clinic, and normal controls were drawn in
the same way.
Platelet counts and protein S assay
Platelet counts and plasma protein S activities were car-
ried out by the clinical pathology laboratories, University
of Miami. Normal ranges of values were used for refer-
ence.
Platelet microparticle (PMP) assay
The method as described by Jy et al. [8,9] was employed
with minor modifications [10,11]. Briefly, platelet-rich
plasma (PRP) was prepared by centrifuging whole blood
10 min. at 160 × g. Platelet-poor plasma (PPP) was then
prepared by centrifuging PRP for 6 min. at 2000 × g. Five
μL of fluorescein isothiocyanate (FITC)-conjugated anti-
CD41 was added to 20 μL of PPP, and after 20 min., 25 μL
of 4% PFA fixative also added. After 20 min. fixation, 2.0
mL of PBS was added and PMP were measured by flow
cytometry with the neutral density filter removed. Events
were detected and counted by triggering on the fluores-
cent signal. Results are expressed as PMP × 107/μL plasma.
Particle counts measured in 1-minute runs were converted
to concentrations in plasma based on the dilution factor
and rate of flow through the cytometer, as detailed [12].
Platelet aggregates (PAg)
Circulating PAg were measured by flow cytometry, as
described [13,14]. This assay reflects the tendency of acti-
vated platelets to form micro-aggregates in circulation.
Platelet activation marker P-selectin (CD62p)
Platelet activation marker P-selectin (CD62p) was meas-
ured by flow cytometry using phycoerythrin (PE)-labeled
anti-CD62p together with platelet marker, anti-CD41, as
described [15,16]. Briefly, to 5 μL of citrated whole blood
was added 100 μL PBS, and then 5 μL of each mAb. After
10 min, 160 μL of 4% PFA in PBS was added. Following
10 min. fixation, 1.0 μL of PBS was added, and after 2
hours hemolysis the sample was ready for cytometry. All
samples were counted for 1 minute.
Platelet-associated IgG, IgM
Platelet associated immunoglobulin was measured as
described [17], except that the F(ab)2 fragment of goat
anti-human IgG and IgM was employed to reduce non-
specific Fc-dependent binding, thus increasing accuracy of
the measurement. In our method, fresh platelets are iso-
lated in the presence of 2 mM EGTA and 2 μM prostaglan-
din E1, preventing activation and emergence of internal
IgG and IgM on the platelet surface, thereby avoiding
objections sometimes raised regarding measurement of
platelet-associated IgG and IgM.
Results
Platelet counts
Mean platelet counts for the n = 33 patients were within
the normal range (261 ± 95 × 103/μL, ± S.D.), as com-
pared with the reference value for the normal controls
(259 ± 90 × 103/μL) studied concomitantly; p = NS (Fig-
ure 1A). However, 7 MS patients had platelets counts/μL
<200,000 and 3 had counts ≤150,000 (76,000, 100,000,
150,000), consistent with our experience that mild
thrombocytopenia is not uncommon in MS patients.
Platelet activation marker CD62p
The mean fluorescence intensity of CD62p, a marker of
platelet activation, was also elevated in MS as compared to
controls: mean values ± SD were 4.4 ± 3.6 for the MS and
2.5 ± 1.3 for the controls; p < 0.001 (Figure 1B).Journal of Neuroinflammation 2008, 5:27 http://www.jneuroinflammation.com/content/5/1/27
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Platelet microparticles (PMP)
In the MS group, PMP were elevated by approximately a
two-fold margin compared with the controls (Figure 1C).
The mean value for the MS patients was 5.1 ± 3.4 (× 107/
mL, ± SD), compared to 2.5 ± 0.9 for controls; p < 0.001.
These PMP are released into the plasma in the process of
platelet activation and are known to exhibit procoagulant
activity. This is accomplished by supplying a suitable
phospholipid surface for assembly of the factor X-ase and
factor II-ase (prothrombinase) complexes, known as
platelet factor 3 (PF3) activity [18], and by carrying tissue
factor (TF) [19,20].
Platelet micro-aggregates (PAg)
Circulating platelet micro-aggregates, an additional
marker of platelet activation, was also elevated in the MS
group, relative to controls, p = 0.01, to a degree similar to
the CD62p (data not shown).
Protein S activity
No significant difference was found between the MS and
control groups in this measure (Figure 1D). Values were,
± SD, 105 ± 21% for controls and 116 ± 33% for MS
patients.
Platelet surface-associated IgG, IgM
Immunoglobulin IgM associated with platelets was signif-
icantly elevated in the MS group (7.8 ± 6.5 percent cells
positive) as compared to controls (3.4 ± 1.3), p < 0.01
(Figure 2B). However, IgG was not increased (3.4 ± 2.7 in
MS vs. 2.7 ± 1.3 in controls) (Figure 2A). This IgM may
represent immune complex formation, autoantibody, or
it could reflect chronic platelet activation. Chronic platelet
activation has been reported to cause externalization of
immunoglobulins normally found within platelets. Sur-
face expression of IgM may sensitize the platelet for
destruction by complement [10], or alternatively, by the
reticuloendothelial system.
Discussion
By all three measures (PMP, PAg, CD62p), we have docu-
mented the presence of platelet activation in MS patients.
Increased PMP and increased CD62p expression are
accepted markers of platelet activation [15,21]. Our obser-
vations strongly support the conclusion that platelets are
chronically activated in MS, and support results in the ear-
lier literature [2].
Platelet activation may be an epiphenomenon conse-
quent to the disease process in MS, possibly secondary to
endothelial injury. Indeed, we have reported elevated
plasma endothelial microparticles (EMP) in MS, positive
for platelet endothelial cell adhesion molecule-1 (CD31/
PECAM-1) [22] and suggested that this increase in EMP
may reflect the interaction of activated T-cells with
endothelium. It is also possible that interaction of
released PMP with underlying endothelium contributes
to the endothelial abnormalities involved in the patho-
physiology of MS. Binding of P-selectin on PMPs to P-
selectin glycoprotein ligand-1 (PSGL-1) and PECAM-1 on
lymphocytes is known to induce or increase the expres-
sion of integrins such as integrin α4β1 (VLA-4), and thus
facilitate lymphocyte binding to endothelium [23]. How-
ever; the in vivo role of CD62p+ PMP and CD31+ EMP and
their interactions in MS remains unknown. It is known
that PMP can transport a variety of bioactive agents
including platelet activating factor (PAF), amyloid precur-
sor protein, complement factors, and other molecules
[24,25], all of which could contribute to the disease proc-
ess in some manner.
Comparison of platelet count, platelet activation marker  CD62P expression, PMP, and protein S between controls  and MS patients Figure 1
Comparison of platelet count, platelet activation 
marker CD62P expression, PMP, and protein S 
between controls and MS patients. (A) Mean platelet 
counts did not differ between the MS and control groups. 
(B) Elevation of platelet activation marker CD62p in the MS 
group was highly significant, *P < 0.001. Not shown or 
included in the analysis was one extremely high value (60.6), 
possibly a technical error. (C) PMP counts in the MS patients 
were significantly higher than controls, *p < 0.001. Not 
shown or included in the analysis was one very high outlying 
value (25.2). (D) Protein S activity (% control) did not differ 
significantly between MS and controls. All values are 
expressed as mean ± SD. The institutional control values 
(mean ± SD) of platelet count and protein S activity were 
obtained from the laboratory of University of Miami Hospital 
and Clinics, and are not shown as individual dots because the 
numbers are too large.Journal of Neuroinflammation 2008, 5:27 http://www.jneuroinflammation.com/content/5/1/27
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Although study of the role of cell-derived microparticles
in disease processes is still in its infancy, it is clear that
PMP are involved in angiogenesis [26,27] and in certain
malignant processes [28,29]. In light of these develop-
ments, it is reasonable to postulate that PMP may play an
active role in the pathogenesis of MS. Several chemokines
have been detected on platelets [30] and some are carried
by PMP [31,32]. The chemokine receptor CXCR4 can be
transferred by PMP from cell to cell [33]. Leukocyte acti-
vation by PMP has been also reported [34], illustrating
another potential link between PMP and the inflamma-
tory disease process.
It remains unclear how platelet activation and the release
of PMP pertain to our clinical observation of 2 cases of ITP
associated with MS at our center. This finding, in accord
with the earlier literature [2], suggests the presence of a
procoagulant state in MS, and elements of the coagulation
system such as fibrin and tissue factor (TF) are found in
MS lesions [35]. However, review of the available litera-
ture has identified additional MS patients with ITP com-
plicating their illness. Granier et al in 2001 reported a 40
year old French patient with well-documented MS who
had a transient thrombocytopenia [36]. Four additional
cases have been identified recently in Spain [37]. How-
ever, two earlier cases [1997] with Hodgkin's and throm-
bocytopenia cannot be accepted as ITP [38]. Recent
epidemiological studies in Maryland [39] and in Nova
Scotia, Canada [40] have brought to light additional
cases. Segal et al. identified 4 such cases in children [39]
and Kirby et al. have identified 22 MS patients with
"immune thrombocytopenia" [40]. Segal's report reflects
a 25-fold higher incidence of ITP in MS in the Maryland
study and, although details from the Canadian study are
not available, an even higher coincidence may occur
there. Although PMPs were thought to possess solely pro-
coagulant properties, it appears that some PMP pheno-
types may exert predominantly anticoagulant functions
by modulating the protein C/S system [41].
Platelet associated IgM was increased in the MS group (p
< 0.01) but platelet associated IgG was not. Our finding of
elevated platelet-associated IgM and platelet activation
may reflect the presence low levels of serum anti-phos-
pholipid antibodies in MS. This finding is consistent with
reports of predominately IgM anti-phospholipid antibod-
ies in MS. Sugiyama et al found 14 of 32 patients positive
for IgM anti-phospholipid antibody but only 3 of 32 pos-
itive for IgG [42]. Using another method, we have found
anti-phospholipid antibodies exclusively of IgM class in
MS [43]. Patients with the anti-phospholipid syndrome
are prone to recurrent stroke, thrombocytopenia, and
neurological manifestations resembling those of MS are
possible [44].
As the figures show, not all MS patients show elevated
platelet activation or platelet-associated IgM. Since this
study was not longitudinal, it is not known if the patients
with elevated values represent a subset of MS patients, or
if most MS patients have occasional or episodic eleva-
tions, possibly preceding exacerbations.
The classic neuropathology of MS consists of the perive-
nular plaque surrounding venular endothelial cells with
infiltrating lymphocytes and macrophages [45]. The inter-
actions of these cellular elements and resulting myelin
and axonal damage are complex and incompletely under-
stood. Our findings collectively suggest a complex inter-
play of platelets with endothelial and other cells in the
pathogenesis of the MS plaque. The interaction of CD62p,
PMP, macrophages, anti-phospholipid antibodies, and
the CNS venular endothelium requires further study.
Conclusion
Findings of this study demonstrate that platelets are sig-
nificantly activated in MS patients. However, their role in
pathogenesis of MS remains unknown. Further longitudi-
nal studies of larger cohorts of MS patients are required to
validate the significance of the present study and demon-
Comparison of platelet-associated IgG and IgM between con- trols and MS patients Figure 2
Comparison of platelet-associated IgG and IgM 
between controls and MS patients. Results are 
expressed as percentage of platelets positive for the indi-
cated immunoglobulin, where positive is defined as >3SD 
above the mean for normal subjects in this laboratory by the 
procedure referenced in the methods section. (A) Results 
for platelet-associated IgG showed no significant difference 
between the MS group and controls. Value were, ± SD: 2.7 ± 
1.3 for controls vs. 3.4 ± 2.7. (B) In contrast, mean platelet 
associated IgM was significantly higher in the MS group, *p < 
0.01. Values were, ± SD: 3.4 ± 1.3 for controls vs. 7.8 ± 6.5 
for MS. Not shown or included in analysis were 2 very high 
outlying values (55.9, 65.9).Journal of Neuroinflammation 2008, 5:27 http://www.jneuroinflammation.com/content/5/1/27
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strate the role of platelet activation in neuro-pathogenesis
of MS.
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